BTK and mantle cell lymphoma: Moreover, BCR signaling inhibitors like the Bruton tyrosine kinase (BTK) inhibitor ibrutinib showed very promising efficacy in MCL patients (see below) which further suggest an important and ongoing role of the BCR in MCL [65].